DKDCA vs. ISPC, NTBL, GMVDF, AGRX, MBIO, SXTP, ONCO, BPTSY, ELOX, and IONM
Should you be buying Data Knights Acquisition stock or one of its competitors? The main competitors of Data Knights Acquisition include iSpecimen (ISPC), Notable Labs (NTBL), G Medical Innovations (GMVDF), Agile Therapeutics (AGRX), Mustang Bio (MBIO), 60 Degrees Pharmaceuticals (SXTP), Onconetix (ONCO), Biophytis (BPTSY), Eloxx Pharmaceuticals (ELOX), and Assure (IONM). These companies are all part of the "medical" sector.
Data Knights Acquisition (NASDAQ:DKDCA) and iSpecimen (NASDAQ:ISPC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk, community ranking and media sentiment.
35.3% of Data Knights Acquisition shares are owned by institutional investors. Comparatively, 13.6% of iSpecimen shares are owned by institutional investors. 45.7% of Data Knights Acquisition shares are owned by insiders. Comparatively, 32.7% of iSpecimen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Data Knights Acquisition and Data Knights Acquisition both had 1 articles in the media. iSpecimen's average media sentiment score of 1.29 beat Data Knights Acquisition's score of 0.00 indicating that iSpecimen is being referred to more favorably in the news media.
Data Knights Acquisition has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
Data Knights Acquisition has a net margin of 0.00% compared to iSpecimen's net margin of -124.84%. Data Knights Acquisition's return on equity of 0.00% beat iSpecimen's return on equity.
Data Knights Acquisition has higher earnings, but lower revenue than iSpecimen. Data Knights Acquisition is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
iSpecimen received 3 more outperform votes than Data Knights Acquisition when rated by MarketBeat users.
Summary
Data Knights Acquisition beats iSpecimen on 7 of the 12 factors compared between the two stocks.
Get Data Knights Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for DKDCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DKDCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DKDCA vs. The Competition
Data Knights Acquisition Competitors List
Related Companies and Tools
